These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 3106757

  • 1. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW, McNatt LG, Chandler ML, York BM.
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [Abstract] [Full Text] [Related]

  • 2. Spiro hydantoin aldose reductase inhibitors.
    Sarges R, Schnur RC, Belletire JL, Peterson MJ.
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT, Fuller RW, Broderick CL, Hemrick-Luecke SK, Perry KW.
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF, Lee JW, Fujisawa S, Blessing K, Lou MF.
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [Abstract] [Full Text] [Related]

  • 7. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of aldehyde reductase by aldose reductase inhibitors.
    Sato S, Kador PF.
    Biochem Pharmacol; 1990 Sep 01; 40(5):1033-42. PubMed ID: 2117925
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct 01; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ, Sarges R, Aldinger CE, MacDonald DP.
    Adv Exp Med Biol; 1979 Oct 01; 119():347-56. PubMed ID: 115231
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A.
    Jpn J Pharmacol; 1997 Feb 01; 73(2):133-44. PubMed ID: 9074947
    [Abstract] [Full Text] [Related]

  • 18. The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
    Poulsom R, Mirrlees DJ, Earl DC, Heath H.
    Exp Eye Res; 1983 May 01; 36(5):751-60. PubMed ID: 6406254
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.